

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Making progress in a rare disease: emerging... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-1737/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-1737" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas" />
    
            <meta name="og:title" content="F1000Research Article: Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas.">
            <meta name="og:description" content="Read the latest article version by Jennifer Choe, Richard Riedel, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="17324">
            <meta name="article-id" content="15868">
            <meta name="dc.title" content="Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas">
            <meta name="dc.description" content="Sarcomas are rare tumors derived from mesenchymal connective tissues in the body. Because there are well over 50 histologic sarcoma subtypes, including malignant and non-malignant pathologies, clinical courses and therapeutic management are widely divergent. In general, therapeutic options across all soft tissue sarcomas are limited in number and are often generalized across multiple sarcoma histologies. The recent emergence of molecularly targeted therapies and immune-based agents presents a future of refined systemic treatment practices that are rationally tailored to the tumor by histologic subtype and biologic mechanisms.">
            <meta name="dc.subject" content="Soft tissue sarcoma, novel therapies, immunotherapy">
            <meta name="dc.creator" content="Choe, Jennifer">
            <meta name="dc.creator" content="Riedel, Richard">
            <meta name="dc.date" content="2018/11/02">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.15868.1">
            <meta name="dc.source" content="F1000Research 2018 7:1737">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Soft tissue sarcoma">
            <meta name="prism.keyword" content="novel therapies">
            <meta name="prism.keyword" content="immunotherapy">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/11/02">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="1737">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.15868.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-1737">
            <meta name="citation_title" content="Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas">
            <meta name="citation_abstract" content="Sarcomas are rare tumors derived from mesenchymal connective tissues in the body. Because there are well over 50 histologic sarcoma subtypes, including malignant and non-malignant pathologies, clinical courses and therapeutic management are widely divergent. In general, therapeutic options across all soft tissue sarcomas are limited in number and are often generalized across multiple sarcoma histologies. The recent emergence of molecularly targeted therapies and immune-based agents presents a future of refined systemic treatment practices that are rationally tailored to the tumor by histologic subtype and biologic mechanisms.">
            <meta name="citation_description" content="Sarcomas are rare tumors derived from mesenchymal connective tissues in the body. Because there are well over 50 histologic sarcoma subtypes, including malignant and non-malignant pathologies, clinical courses and therapeutic management are widely divergent. In general, therapeutic options across all soft tissue sarcomas are limited in number and are often generalized across multiple sarcoma histologies. The recent emergence of molecularly targeted therapies and immune-based agents presents a future of refined systemic treatment practices that are rationally tailored to the tumor by histologic subtype and biologic mechanisms.">
            <meta name="citation_keywords" content="Soft tissue sarcoma, novel therapies, immunotherapy">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Jennifer Choe">
            <meta name="citation_author_institution" content="Duke University Medical Center, Durham, NC, USA">
            <meta name="citation_author" content="Richard Riedel">
            <meta name="citation_author_institution" content="Duke University Medical Center, Durham, NC, USA">
            <meta name="citation_publication_date" content="2018/11/02">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="1737">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.15868.1">
            <meta name="citation_firstpage" content="1737">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-1737/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-1737.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=17324 /> <input type=hidden id=articleId name=articleId value=15868 /> <input type=hidden id=xmlUrl value="/articles/7-1737/v1/xml"/> <input type=hidden id=xmlFileName value="-7-1737-v1.xml"> <input type=hidden id=article_uuid value=35a64fa8-520d-49be-8cc3-e10084333a24 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.15868.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.15868.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-1737"
  },
  "headline": "Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas",
  "datePublished": "2018-11-02T12:42:42",
  "dateModified": "2018-11-02T12:42:42",
  "author": [
    {
      "@type": "Person",
      "name": "Jennifer Choe"
    },    {
      "@type": "Person",
      "name": "Richard Riedel"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Sarcomas are rare tumors derived from mesenchymal connective tissues in the body. Because there are well over 50 histologic sarcoma subtypes, including malignant and non-malignant pathologies, clinical courses and therapeutic management are widely divergent. In general, therapeutic options across all soft tissue sarcomas are limited in number and are often generalized across multiple sarcoma histologies. The recent emergence of molecularly targeted therapies and immune-based agents presents a future of refined systemic treatment practices that are rationally tailored to the tumor by histologic subtype and biologic mechanisms."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-1737",
            "name": "Making progress in a rare disease: emerging therapeutics in soft tissue..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Making progress in a rare disease: emerging therapeutics in soft tissue... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=17324 data-id=15868 data-downloads="" data-views="" data-scholar="10.12688/f1000research.15868.1" data-recommended="" data-doi="10.12688/f1000research.15868.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-1737/v1/pdf?article_uuid=35a64fa8-520d-49be-8cc3-e10084333a24" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-15868-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-15868-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-15868-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Choe J and Riedel R. Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1737 (<a class=new-orange href="https://doi.org/10.12688/f1000research.15868.1" target=_blank>https://doi.org/10.12688/f1000research.15868.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-15868-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=15868 id=track-article-signin-15868 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/15868?target=/articles/7-1737">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=17324 /> <input name=articleId type=hidden value=15868 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:jennifer.choe@duke.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Jennifer Choe</span></a>,&nbsp;</span><span class=""><a href="mailto:richard.riedel@duke.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Richard Riedel</span></a><a href="https://orcid.org/0000-0001-5412-8710" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-5412-8710</div></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:jennifer.choe@duke.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Jennifer Choe</span></a>,&nbsp;</span><span class=""><a href="mailto:richard.riedel@duke.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Richard Riedel</span></a><a href="http://orcid.org/0000-0001-5412-8710" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-5412-8710</div></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 02 Nov 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.15868.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Duke University Medical Center, Durham, NC, USA<br/> <p> <div class=margin-bottom> Jennifer Choe <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Richard Riedel <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=18252-39842></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=40772-39841></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Sarcomas are rare tumors derived from mesenchymal connective tissues in the body. Because there are well over 50 histologic sarcoma subtypes, including malignant and non-malignant pathologies, clinical courses and therapeutic management are widely divergent. In general, therapeutic options across all soft tissue sarcomas are limited in number and are often generalized across multiple sarcoma histologies. The recent emergence of molecularly targeted therapies and immune-based agents presents a future of refined systemic treatment practices that are rationally tailored to the tumor by histologic subtype and biologic mechanisms. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Soft tissue sarcoma, novel therapies, immunotherapy </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Jennifer Choe (<a href="mailto:jennifer.choe@duke.edu">jennifer.choe@duke.edu</a>) <br> Richard Riedel (<a href="mailto:richard.riedel@duke.edu">richard.riedel@duke.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding authors:</b> Jennifer Choe, Richard Riedel </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> Jennifer H. Choe has received institutional clinical research support from Blueprint Medicines, Genmab, and AstraZeneca. Richard F. Riedel has received institutional clinical research support from AADi, AROG, Karyopharm, Ignyta, Immune Design, Lilly, NanoCarrier, Novartis, Oncternal, Plexxikon, Threshold, and TRACON and has served as a consultant or advisor for Bayer, EISAI, EMD Serono, Janssen, Lilly, and Loxo. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2018 Choe J and Riedel R. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Choe J and Riedel R. Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1737 (<a href="https://doi.org/10.12688/f1000research.15868.1" target=_blank>https://doi.org/10.12688/f1000research.15868.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 02 Nov 2018, <b>7</b>(F1000 Faculty Rev):1737 (<a href="https://doi.org/10.12688/f1000research.15868.1" target=_blank>https://doi.org/10.12688/f1000research.15868.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 02 Nov 2018, <b>7</b>(F1000 Faculty Rev):1737 (<a href="https://doi.org/10.12688/f1000research.15868.1" target=_blank>https://doi.org/10.12688/f1000research.15868.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d21312e167>Introduction</h2><p class="" id=d21312e170>Soft tissue sarcomas (STS) represent a heterogeneous group of rare mesenchymal neoplasms with varied clinical presentations and behavior. In 2018, 13,040 new cases will be diagnosed<sup><a href="#ref-1">1</a></sup>. Over 50 histologic subtypes have been identified, with the most commonly represented subtypes including gastrointestinal stromal tumors (GISTs), undifferentiated pleomorphic sarcomas, liposarcomas, and leiomyosarcomas. They can occur anywhere in the body and have widely variable clinical courses ranging from indolent to highly aggressive. In general, the most common sites of presentation are the extremities, but histologic subtypes demonstrate predilections for various parts of the body. The heterogeneity of histologic subtypes creates significant obstacles in identifying unifying treatment strategies across the many subtypes, since the rarity of these tumors has posed limitations in adequately powering clinical trials. The vast differences in biologic drivers of disease and clinical behavior have posed tremendous challenges to the development of effective treatment options for these tumors. Increasingly, clinical trials for STS have become more focused on specific histologic subtypes or tissue-agnostic molecular drivers of disease. The emergence of rationally designed studies and novel experimental therapeutics promises hope for expanded treatment options for patients with unresectable and metastatic STS. Here, we describe the most promising therapies to affect sarcoma management in the near future.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21312e180>Gastrointestinal stromal tumors</h2><p class="" id=d21312e183>GISTs represent one of the most commonly diagnosed STS. Roughly 5,000 new cases are diagnosed in the United States annually. These tumors can occur anywhere along the GI tract and are thought to be derived from the interstitial cells of Cajal, the pacemakers of the gastrointestinal tract. GISTs are most commonly found in the stomach (60%), small intestine (30–35%), and other locations in the GI tract (&lt;10%)<sup><a href="#ref-2">2</a></sup>. Gain-of-function mutations in the growth factor receptor genes for KIT (CD117) and platelet-derived growth factor α (PDGFRA) drive tumor development in 85–90% of GISTs to promote constitutive activation of growth factor signaling pathways that cause uncontrolled cell proliferation.</p><p class="" id=d21312e190>GISTs are considered unresponsive to traditional cytotoxic chemotherapies and radiation. Prior to 2000, no effective systemic therapeutic options existed for patients with unresectable or metastatic disease. In 2000, the first report of response to the tyrosine kinase inhibitor (TKI) imatinib mesylate was published, and this was soon followed by an open-label randomized multi-center clinical trial in 147 patients that demonstrated partial response in 53.7% and stable disease in 27.9% of patients<sup><a href="#ref-3">3</a>,<a href="#ref-4">4</a></sup>. Multiple subsequent trials have now firmly established imatinib as the first-line systemic therapy for the management of GISTs. Two other TKIs have since been approved by the US Food and Drug Administration (FDA) for the treatment of GISTs, including sunitinib and regorafenib. Both of these have limited response rates (14% for sunitinib and 4.5% for regorafenib) but did demonstrate improved progression-free survival (PFS) compared to placebo in phase III trials<sup><a href="#ref-5">5</a>,<a href="#ref-6">6</a></sup>. While imatinib re-introduction after progression on approved agents has demonstrated an improved PFS over placebo, the duration of benefit is transient (imatinib versus placebo 1.8 versus 0.9 months; <i>p</i>=0.009)<sup><a href="#ref-7">7</a></sup>. Other TKIs, such as pazopanib, sorafenib, and nilotinib, have demonstrated marginal activity but may be considered as “off-label” options when clinical trial options are unavailable<sup><a href="#ref-8">8</a>–<a href="#ref-11">11</a></sup>.</p><p class="" id=d21312e221>Mutational status of KIT and PDGFRA is crucial to predicting response rates and durability of response to imatinib therapy. The most common mutations found in untreated GISTs are in the juxtamembrane region, specifically in exon 11 (70%) and exon 9 (15%), with up to another 10% of primary mutations being found in PDGFRA<sup><a href="#ref-12">12</a></sup>. KIT exon 11 mutations and insertions portend favorable prognosis, while deletions in exon 11 and exon 9 portend decreased durability of response and shorter survival rates<sup><a href="#ref-13">13</a></sup>. The most common PDGFRA mutation is the D842V substitution in the activation loop of PDGFRA. Tumors harboring this mutation are refractory to nearly all available treatment options and are associated with poor outcomes with a short PFS of only 2.8 months with imatinib<sup><a href="#ref-14">14</a></sup>.</p><p class="" id=d21312e236>The major challenge facing the treatment of GISTs remains resistance to currently available targeted therapies. Imatinib functions by binding the ATP-binding pocket for KIT and PDGFRA to prevent the activation of downstream signaling. Development of mutations in the ATP-binding pocket or activation loop decreases the drug’s binding affinity, leading to TKI resistance. The most commonly found secondary resistance mutations are encoded in exons 13 and 14 of the ATP-binding pocket and in exons 17 and 18 of the activation loop. About 14% of tumors have primary resistance to imatinib (progression within the first 6 months of treatment), while in 40–50% of tumors secondary resistance due to acquired mutations in KIT or PDGFRA develops after about 2 years on imatinib treatment<sup><a href="#ref-3">3</a>,<a href="#ref-12">12</a></sup>. Activation loop mutations accumulate with sunitinib treatment. For sunitinib and regorafenib, resistance typically develops within approximately 6 months of therapy<sup><a href="#ref-5">5</a>,<a href="#ref-6">6</a></sup>. Selection of agents based on the initiating and acquired resistance mutations in KIT and PDGFRA will hopefully expand systemic options beyond the three currently approved TKIs.</p><p class="" id=d21312e254>Currently, no approved treatment options are available for the highly resistant PDGFRA D842V exon 18 activation loop mutation. However, a number of promising therapeutic agents have emerged. Crenolanib has been specifically developed to target this mutation and demonstrated a clinical benefit rate of 31% in 16 patients<sup><a href="#ref-15">15</a></sup>. A randomized phase III study is currently underway evaluating the efficacy of crenolanib compared to placebo in patients with PDGFRA D842V tumors (CrenoGIST: NCT02847429)<sup><a href="#ref-16">16</a></sup>.</p><p class="" id=d21312e265>BLU-285, also known as avapritinib, and DCC-2618 are highly potent and selective inhibitors of mutant KIT and PDGFRA, with demonstrated activity against PDGFRA D842V mutations along with secondary KIT resistance mutations. BLU-285 is a selective inhibitor of KIT and PDGFRA activation loop mutants<sup><a href="#ref-17">17</a></sup>. While BLU-285 demonstrated strong activity against clinically relevant single mutations in either the activation loop or the ATP-binding pocket of KIT and PDGFRA, tumor sensitivity was increased in the setting of dual mutants of the juxtamembrane and ATP-binding pocket and protein regions (e.g. exon 11/exon 17). In a phase I study of BLU-285, all 31 patients with D842V PDGFRA GISTs demonstrated a tumor response<sup><a href="#ref-18">18</a></sup>. A phase III study of BLU-285 compared to regorafenib in the third-line setting is planned (VOYAGER: NCT03465722).</p><p class="" id=d21312e276>DCC-2618 is a pan-KIT and PDGFRA inhibitor with activity against both initiating and acquired resistance mutations (KIT exons 9, 11, 13, 14, 17, and 18 and PDGFRA exon 18). Updated results from a phase I study of 57 heavily pre-treated GIST patients with two or more prior agents were presented at the European Society of Medical Oncology (ESMO) 2017 meeting, revealing a disease control rate of 76% at 12 weeks. DCC-2618 showed partial metabolic response in 69% of patients with KIT or PDGFRA mutants<sup><a href="#ref-19">19</a></sup>. Based on these encouraging results, a randomized phase III pivotal study in GIST patients for treatment in the fourth-line setting is ongoing (INVICTUS: NCT03353753). A second randomized phase III study in the second line versus sunitinib is planned.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21312e286>Non-gastrointestinal stromal tumor soft tissue sarcomas</h2><div class=section><a name=d21312e289 class=n-a></a><h3 class=section-title>Unselected soft tissue sarcomas</h3><p class="" id=d21312e294>With the exception of GISTs, clinical studies examining treatment for sarcomas historically included unselected patient populations. Treatment efficacy for these studies typically combined data for all histologic subtypes given the challenges in recruiting for adequately powered phase III studies for selected subpopulations. As a result, systemic options have traditionally been generalized to all STS despite limited patients enrolled for an individual subtype.</p><p class="" id=d21312e297>The mainstay of STS management is cytotoxic chemotherapy. Most commonly, the first-line treatment is an anthracycline-based regimen. Other combinations and cytotoxic agents commonly used have traditionally included gemcitabine-based regimens, single-agent dacarbazine, and single-agent ifosfamide. The multi-targeted TKI pazopanib was FDA approved for STS in 2012<sup><a href="#ref-20">20</a></sup>. In general, however, response rates with cytotoxic agents have been relatively low, with short PFS intervals and associated toxicity.</p><p class="" id=d21312e304>Despite the obstacles faced in a “one-size-fits-all” treatment mentality, some recent treatments have emerged for unselected sarcomas. In a randomized, double-blind, phase II study, the multikinase inhibitor regorafenib demonstrated improvements in PFS in some anthracycline-refractory STS<sup><a href="#ref-21">21</a></sup>. Selected subtype clinical trials with regorafenib are currently ongoing (NCT02048371 and NCT02048722). The doxorubicin pro-drug aldoxorubicin demonstrated improved PFS compared to doxorubicin in a multicenter, randomized, phase IIb trial<sup><a href="#ref-22">22</a></sup>. In addition, a significantly improved cardiotoxicity profile was observed<sup><a href="#ref-23">23</a></sup>. The most pivotal advance in the treatment of STS was observed in a phase I/II study examining the combination of the PDGFRA antibody olaratumab with doxorubicin<sup><a href="#ref-24">24</a></sup>. While the study met its pre-defined primary endpoint, with an improvement in PFS of 2.5 months, it demonstrated a striking improvement in median overall survival (OS) of 11.8 months (26.5 months versus 14.7 months, <i>p</i>=0.0003) for the combination compared to doxorubicin monotherapy, resulting in FDA approval. A phase III confirmatory study with the combination is fully enrolled, and the results are eagerly awaited (ANNOUNCE: NCT02451943). Ongoing studies are exploring olaratumab in combination with gemcitabine/docetaxel (ANNOUNCE2: NCT02659020) as well as doxorubicin/ifosfamide (NCT03283696).</p></div><div class=section><a name=d21312e327 class=n-a></a><h3 class=section-title>Selected soft tissue sarcomas</h3><p class="" id=d21312e332>The recognition for therapy tailored to histologic subtype and molecular drivers has led to a shift in the approach to clinical trial design for STS. This is demonstrated by the higher sensitivities of certain histologies to specific chemotherapies, such as paclitaxel for angiosarcoma or ifosfamide for synovial sarcoma<sup><a href="#ref-25">25</a>,<a href="#ref-26">26</a></sup>.</p><p class="" id=d21312e342>Liposarcomas and leiomyosarcomas, or so-called “L-type” sarcomas, comprise nearly half of unresectable and metastatic adult STS and therefore represent the largest STS population in need of therapeutic options. Liposarcomas, with the potential exception of myxoid liposarcomas, are considered relatively insensitive to chemotherapy. Eribulin and trabectedin are recently approved agents that have demonstrated modest activity in the L-type sarcomas. In a phase III study, patients with liposarcomas and leiomyosarcomas were randomized to receive either the microtubule polymerization inhibitor eribulin or dacarbazine<sup><a href="#ref-27">27</a></sup>. While eribulin improved OS by 2 months in comparison to dacarbazine (13.5 versus 11.5 months, hazard ratio [HR] 0.77, 95% confidence interval [CI] 0.62–0.95, <i>p</i>=0.0169) for all subjects enrolled, the benefit was seen primarily in the liposarcoma cohort. Based on these results, FDA approval for eribulin was granted in 2016 for use in liposarcomas but not for leiomyosarcomas. A recently published histology-specific subgroup analysis of liposarcomas revealed an improvement in OS of 15.6 months versus 8.4 months (HR 0.51, 95% CI 0.35–0.75, <i>p</i>&lt;0.001) in addition to a PFS benefit of 2.9 versus 1.7 months (HR 0.52, 95% CI 0.35–0.78, <i>p</i>=0.0015)<sup><a href="#ref-28">28</a></sup>.</p><p class="" id=d21312e362>The DNA damage modulator trabectedin gained FDA approval for liposarcomas and leiomyosarcomas in 2015. While the phase III study failed to meet its primary endpoint of improved OS, trabectedin was approved based on a PFS benefit of 4.2 months compared to 1.5 months for dacarbazine (HR 0.55, 95% CI 0.44–0.70, <i>p</i>&lt;0.001)<sup><a href="#ref-29">29</a></sup>. In published phase II and phase III studies, trabectedin appeared to be more effective in myxoid liposarcomas<sup><a href="#ref-29">29</a>,<a href="#ref-30">30</a></sup>.</p><p class="" id=d21312e379>The SINE (XPO-1) inhibitor selinexor is being explored in ongoing studies in dedifferentiated liposarcoma. Phase Ib results published in 2016 demonstrated stable disease in 7 of 15 (47%) patients for ≥4 months<sup><a href="#ref-31">31</a></sup>. An ongoing randomized, multi-center, double-blind, placebo-controlled phase II/III study is evaluating selinexor versus placebo in 245 patients with dedifferentiated liposarcoma. Results from the phase II portion of the study were presented at the 2018 American Society of Clinical Oncology (ASCO) meeting and revealed an improved PFS of 5.6 months versus 1.8 months by RECIST v1.1 criteria<sup><a href="#ref-32">32</a></sup>.</p><p class="" id=d21312e391>In a phase II study, the multi-targeted TKI anlotinib demonstrated activity in leiomyosarcoma and synovial sarcoma and appeared particularly promising in alveolar soft part sarcoma (ASPS)<sup><a href="#ref-33">33</a></sup>. A phase III study with anlotinib in these three subtypes is actively recruiting (APROMISS: NCT03016819). In results presented at ASCO 2018, patients with the typically chemotherapy-insensitive ASPS demonstrated an improvement in median PFS of 18.23 months compared to 3 months for placebo (HR 0.14, 95% CI 1.19–4.81, <i>p</i>&lt;0.0001) in 56 ASPS patients<sup><a href="#ref-34">34</a></sup>.</p><p class="" id=d21312e405>Angiosarcomas are tumors derived from endothelial cells. Given the role of the vascular endothelial growth factor (VEGF) family of angiogenic factors, TKI therapies with anti-VEGF activity have been tested in sarcoma with variable results. Pazopanib has demonstrated similar efficacy in angiosarcomas as compared to other STS<sup><a href="#ref-20">20</a>,<a href="#ref-35">35</a></sup>. Other TKIs, such as sorafenib, have shown the ability to provide stable disease<sup><a href="#ref-36">36</a></sup>. The benefit of the anti-VEGF monoclonal antibody bevacizumab in the treatment of unselected STS, including angiosarcomas, appears limited<sup><a href="#ref-37">37</a>–<a href="#ref-39">39</a></sup>.</p><p class="" id=d21312e426>TRC105 is a novel antibody directed against endoglin, a molecule upregulated as a possible mechanism of resistance in response to VEGF inhibition and particularly densely expressed in angiosarcomas<sup><a href="#ref-40">40</a>,<a href="#ref-41">41</a></sup>. In a phase Ib/II trial, a small cohort of 18 angiosarcoma patients treated with TRC105 in combination with pazopanib or as a single agent followed by the addition of pazopanib at progression revealed a PFS of 5.59 months for the combination therapy, including two complete responses<sup><a href="#ref-42">42</a></sup>. A randomized phase III study of TRC105 in combination with pazopanib versus pazopanib alone in cutaneous and non-cutaneous angiosarcoma is ongoing (TAPPAS: NCT02979899).</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21312e444>Locally aggressive non-malignant soft tissue tumors</h2><p class="" id=d21312e447>Although not classified as malignant given the lack of metastatic potential, certain connective soft tissue tumors cause significant morbidity owing to locally infiltrative disease and mass effect with a high propensity for local recurrence. These include desmoid tumors and tenosynovial giant cell tumors (TGCTs)/pigmented villonodular synovitis (PVNS).</p><p class="" id=d21312e450>Historically, the management of desmoid tumors included surgical resection, but, given the morbidity and high local recurrence rates, conservative measures, in particular observation, are now increasingly favored. In symptomatic desmoid tumors, new therapies have arisen that target proliferative mechanisms of tumor growth. No FDA-approved therapies exist for desmoid tumors, and the selection of systemic therapy is based, in part, on patient preference and co-morbidities. Efficacy data are limited to small retrospective studies for traditional agents, including non-steroidal anti-inflammatory drugs (NSAIDs), anti-hormonal drugs, and cytotoxic agents such as liposomal doxorubicin. Because of increased expression of c-KIT and PDGFRA/B, TKIs such as imatinib and sorafenib have been investigated as potential therapies. Phase II studies with imatinib demonstrated low response rates from 5–19% with a 6-month PFS of 63%<sup><a href="#ref-43">43</a>–<a href="#ref-45">45</a></sup>. Slightly improving upon this, a retrospective study of 26 patients receiving sorafenib showed an objective response in 25% and symptomatic clinical benefit in 70% of patients<sup><a href="#ref-46">46</a></sup>. This prompted a randomized, double-blind phase III study of sorafenib versus placebo in 87 patients. At interim analysis, this study showed that sorafenib showed a benefit of PFS, which was not reached, compared to 11.3 months for placebo (HR 0.14, 95% CI 0.06–0.33, <i>p</i>&lt;0.0001) and an objective response rate of 33% for sorafenib versus 20% in the placebo group (Alliance A091105: NCT02066181)<sup><a href="#ref-47">47</a></sup>. A 20% response rate was observed for patients who received placebo, reinforcing observation as an option for these patients given the potential for spontaneous regression.</p><p class="" id=d21312e471>In TGCTs/PVNS, a translocation involving the colony-stimulating factor (CSF1) gene promotes proliferative inflammation of the synovium through the recruitment of tumor-associated macrophage cells expressing the CSF1 receptor (CSF1R)<sup><a href="#ref-48">48</a>,<a href="#ref-49">49</a></sup>. Surgical resection is the mainstay of treatment but has the potential for significant morbidity and high risk for local recurrence. Previously, TGCTs/PVNS had no effective medical therapies. TKIs with activity against the CSF1/CSF1R pathway, such as imatinib and nilotinib, have previously been evaluated with limited objective responses, although disease stabilization was seen in a majority of patients<sup><a href="#ref-50">50</a>,<a href="#ref-51">51</a></sup>. The TKI pexidartinib (PLX3397) blocks the CSF1/CSF1R axis, which inhibits tumor-associated macrophage infiltration along with autocrine and paracrine signaling of CSF1 to inhibit tumor cell growth<sup><a href="#ref-52">52</a></sup>. A marked objective response and durable response in some patients was seen in early studies resulting in the development of the phase III ENLIVEN study (NCT02371369)<sup><a href="#ref-53">53</a>,<a href="#ref-54">54</a></sup>. In this study, 120 patients were randomized to either pexidartinib or placebo. A 39% overall response rate (ORR) at week 25 with no further progression at the median 6-month follow-up was seen in responders, which was a vast improvement over prior systemic therapies. Improvements were seen also in a number of functional and symptom scales. In addition, emactuzumab, a monoclonal antibody targeting CSF1R, showed an 86% objective response rate in a phase I study of TGCT/PVNS patients<sup><a href="#ref-55">55</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21312e506>Immunotherapy</h2><p class="" id=d21312e509>With the excitement of immune checkpoint blockade in many tumor types, a number of trials have evaluated immunotherapy in the setting of metastatic STS. In general, responses have been limited across a broad range of histologic subtypes. However, selected subtypes of STS appear to demonstrate potential activity. These include undifferentiated pleomorphic sarcomas and dedifferentiated liposarcomas with objective response rates of 40% and 20%, respectively (n=10 for each histologic subtype), with pembrolizumab monotherapy in the SARC028 study<sup><a href="#ref-56">56</a></sup>. In the ALLIANCE study of nivolumab with or without ipilimumab, nivolumab monotherapy demonstrated a response rate of 5%, while the combination of nivolumab with ipilimumab revealed a response rate of 16%<sup><a href="#ref-57">57</a></sup>. Combination immune checkpoint strategies continue to be evaluated in multiple histology-specific phase I/II studies. In data presented at the 2018 ASCO annual meeting, pembrolizumab combined with axitinib, a small molecule inhibitor targeting VEGFR, c-KIT, and PDGFR, demonstrated promising activity in STS, particularly in ASPS, where an ORR of 45% was reported with preliminary evidence of durable responses<sup><a href="#ref-58">58</a></sup>. Case reports and small case series have additionally supported the concept of checkpoint inhibition in ASPS<sup><a href="#ref-59">59</a>,<a href="#ref-60">60</a></sup>.</p><p class="" id=d21312e531>Novel strategies of targeting tumor antigens, such as New York esophageal squamous cell carcinoma 1 (NY-ESO-1), are under active investigation and include adoptive T-cell transfer, chimeric antigen receptor-T cell, and vaccine-based therapies. These are being explored particularly in synovial and myxoid/round cell liposarcoma where &gt;80% of tumors express the antigen (NCT03520959)<sup><a href="#ref-61">61</a>–<a href="#ref-63">63</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21312e545>Neurotrophic tyrosine receptor kinase-targeted therapies</h2><p class="" id=d21312e548>The recent emergence of agents targeting neurotrophic tyrosine receptor kinase (NTRK) has generated significant excitement given case reports of marked responses in NTRK-rearranged sarcomas<sup><a href="#ref-64">64</a></sup>. These molecularly targeted agents are currently under study in tissue-agnostic phase II basket studies. In the NAVIGATE study, larotrectinib (LOXO-101) demonstrated an 80% ORR in all tumor types, including in 10 of 11 non-GIST STS and 3 of 3 GISTs<sup><a href="#ref-64">64</a></sup>.</p><p class="" id=d21312e559>Entrectinib (RDX-101), an oral inhibitor with activity against NTRK, ROS1, and ALK-rearranged tumors, has shown promising activity in early phase clinical trials and is being studied in the phase II STARTRK-2 study (NCT02568267)<sup><a href="#ref-65">65</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21312e569>Summary of emerging therapeutics in sarcoma</h2><p class="" id=d21312e572>As we enter a new era of precision medicine and immunotherapy, the future of sarcoma appears poised for the discovery of rationally targeted and histology-specific therapeutic agents. The major obstacles facing sarcoma management remain the rarity and heterogeneity of the disease as well as the potential challenges of recruiting enough patients to a subtype-specific trial to make reasonable conclusions about therapeutic efficacy. With these challenges, developmental therapeutics in sarcoma have smartly shifted to targeting the tumors based on biologic mechanisms. A number of therapeutic agents are poised to change the management for some histologic subtypes (<a href="#T1">Table 1</a>). Increased understanding of the molecular pathogenesis of histologic subtypes has widened the therapeutic possibilities. The future will entail taking advantage of the unique biology of each histologic sarcoma subtype and identifying relevant biomarkers to drive therapeutic decision making in order to improve outcomes for this unique patient population.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Ongoing late-phase clinical trials in sarcomas.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d21312e589 class=n-a></a><thead><a name=d21312e591 class=n-a></a><tr><a name=d21312e593 class=n-a></a><th align=center colspan=1 rowspan=1 valign=top><a name=d21312e595 class=n-a></a>Sarcoma subtype</th><th align=center colspan=1 rowspan=1 valign=top><a name=d21312e598 class=n-a></a>Agent(s)</th><th align=center colspan=1 rowspan=1 valign=top><a name=d21312e601 class=n-a></a>Therapeutic target</th><th align=center colspan=1 rowspan=1 valign=top><a name=d21312e604 class=n-a></a>Phase</th><th align=center colspan=1 rowspan=1 valign=top><a name=d21312e607 class=n-a></a>Trial number</th></tr></thead><tbody><a name=d21312e612 class=n-a></a><tr><a name=d21312e614 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21312e616 class=n-a></a> <b>GIST</b> </td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e622 class=n-a></a>BLU-285</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e625 class=n-a></a>PDGFRA D842V Dual<br class=br>mutation (KIT exon 11/17)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e630 class=n-a></a>Phase III</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e633 class=n-a></a>NCT03465722</td></tr><tr><a name=d21312e637 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21312e639 class=n-a></a> <b>GIST</b> </td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e645 class=n-a></a>DCC-2618</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e648 class=n-a></a>KIT exons 9, 11, 13, 14,<br class=br>17, and 18; PDGFRA exon<br class=br>18, including D842V</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e655 class=n-a></a>Phase III</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e658 class=n-a></a>TBD: NCT03353753</td></tr><tr><a name=d21312e662 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21312e664 class=n-a></a> <b>GIST</b> </td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e670 class=n-a></a>Crenolanib</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e673 class=n-a></a>PDGFRA D842V</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e676 class=n-a></a>Phase III</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e679 class=n-a></a>NCT02847429</td></tr><tr><a name=d21312e683 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21312e685 class=n-a></a> <b>Desmoid tumor</b> </td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e691 class=n-a></a>Sorafenib</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e694 class=n-a></a>PDGFR, VEGFR</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e697 class=n-a></a>Phase III</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e700 class=n-a></a>NCT02066181</td></tr><tr><a name=d21312e704 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21312e706 class=n-a></a><b>Unselected soft tissue</b><br class=br><b>sarcoma</b></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e713 class=n-a></a>Doxorubicin/olaratumab</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e716 class=n-a></a>PDGFRA</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e719 class=n-a></a>Phase III</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e722 class=n-a></a>NCT02451943</td></tr><tr><a name=d21312e727 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21312e729 class=n-a></a> <b>Dedifferentiated liposarcoma</b> </td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e735 class=n-a></a>Selinexor</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e738 class=n-a></a>XPO-1</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e741 class=n-a></a>Phase II/III</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e744 class=n-a></a>NCT02606461</td></tr><tr><a name=d21312e748 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21312e750 class=n-a></a><b>Alveolar soft part sarcoma/</b><br class=br><b>synovial sarcoma/</b><br class=br><b>leiomyosarcoma</b></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e760 class=n-a></a>Anlotinib</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e763 class=n-a></a>Multi-target (e.g.<br class=br>VEGFR2/3, PDGFRA/B,<br class=br>KIT)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e770 class=n-a></a>Phase III</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e773 class=n-a></a>NCT03016819</td></tr><tr><a name=d21312e777 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21312e779 class=n-a></a><b>Synovial sarcoma</b></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e783 class=n-a></a>CMB305</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e786 class=n-a></a>NY-ESO-1 vaccine</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e789 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e791 class=n-a></a>NCT03520959</td></tr><tr><a name=d21312e795 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21312e797 class=n-a></a> <b>Angiosarcoma</b> </td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e803 class=n-a></a>TRC105 + pazopanib</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e806 class=n-a></a>Endoglin and VEGFR1/2/3</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e809 class=n-a></a>Phase III</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e812 class=n-a></a>NCT02979899</td></tr><tr><a name=d21312e816 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21312e818 class=n-a></a><b>Tenosynovial giant</b><br class=br><b>cell tumor/pigmented</b><br class=br><b>villonodular synovitis</b> </td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e829 class=n-a></a>Pexidartinib</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e832 class=n-a></a>CSF1R</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e835 class=n-a></a>Phase III</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21312e838 class=n-a></a>NCT02371369</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d21312e846 class=n-a></a><p id=d21312e848> CSF1R, colony-stimulating factor 1 receptor; GIST, gastrointestinal stromal tumor; NY-ESO1, New York esophageal squamous cell carcinoma 1; PDGFRA, platelet-derived growth factor receptor α; VEGFR, vascular endothelial growth factor receptor</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21312e857>Abbreviations</h2><p class="" id=d21312e860>ASCO, American Society of Clinical Oncology; ASPS, alveolar soft part sarcoma; CI, confidence interval; CSF1, colony-stimulating factor 1; CSF1R, colony-stimulating factor 1 receptor; FDA, US Food and Drug Administration; GIST, gastrointestinal stromal tumor; HR, hazard ratio; NTRK, neurotrophic tyrosine receptor kinase; ORR, overall response rate; OS, overall survival; PVNS, pigmented villonodular synovitis; PDGFRA, platelet-derived growth factor receptor α; PFS, progression-free survival; STS, soft tissue sarcoma; TGCT, tenosynovial giant cell tumor; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d21312e1 class=n-a></a><h2 class=main-title id=d21546>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d21312e867 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d21747>References</h2><div class="section ref-list"><a name=d21312e867 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732444477"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e874 class=n-a></a>Siegel RL, Miller KD, Jemal A: Cancer statistics, 2018. <i>CA Cancer J Clin.</i> 2018; <b>68</b>(1): 7–30. <a target=xrefwindow id=d21312e882 href="http://www.ncbi.nlm.nih.gov/pubmed/29313949">PubMed Abstract </a> | <a target=xrefwindow id=d21312e885 href="https://doi.org/10.3322/caac.21442">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732444477">F1000 Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d21312e898 class=n-a></a>Miettinen M, Lasota J: Gastrointestinal stromal tumors: pathology and prognosis at different sites. <i>Semin Diagn Pathol.</i> 2006; <b>23</b>(2): 70–83. <a target=xrefwindow id=d21312e906 href="http://www.ncbi.nlm.nih.gov/pubmed/17193820">PubMed Abstract </a> | <a target=xrefwindow id=d21312e909 href="https://doi.org/10.1053/j.semdp.2006.09.001">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d21312e918 class=n-a></a>Joensuu H, Roberts PJ, Sarlomo-Rikala M, <i> et al.</i>: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. <i>N Engl J Med.</i> 2001; <b>344</b>(14): 1052–6. <a target=xrefwindow id=d21312e929 href="http://www.ncbi.nlm.nih.gov/pubmed/11287975">PubMed Abstract </a> | <a target=xrefwindow id=d21312e932 href="https://doi.org/10.1056/NEJM200104053441404">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d21312e941 class=n-a></a>Demetri GD, von Mehren M, Blanke CD, <i> et al.</i>: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. <i>N Engl J Med.</i> 2002; <b>347</b>(7): 472–80. <a target=xrefwindow id=d21312e952 href="http://www.ncbi.nlm.nih.gov/pubmed/12181401">PubMed Abstract </a> | <a target=xrefwindow id=d21312e955 href="https://doi.org/10.1056/NEJMoa020461">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/719898971"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e964 class=n-a></a>Demetri GD, van Oosterom AT, Garrett CR, <i> et al.</i>: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. <i>Lancet.</i> 2006; <b>368</b>(9544): 1329–38. <a target=xrefwindow id=d21312e975 href="http://www.ncbi.nlm.nih.gov/pubmed/17046465">PubMed Abstract </a> | <a target=xrefwindow id=d21312e978 href="https://doi.org/10.1016/S0140-6736(06)69446-4">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/719898971">F1000 Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717967428"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e992 class=n-a></a>Demetri GD, Reichardt P, Kang YK, <i> et al.</i>: Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet.</i> 2013; <b>381</b>(9863): 295–302. <a target=xrefwindow id=d21312e1003 href="http://www.ncbi.nlm.nih.gov/pubmed/23177515">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1006 href="https://doi.org/10.1016/S0140-6736(12)61857-1">Publisher Full Text </a> | <a target=xrefwindow id=d21312e1010 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3819942">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717967428">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718149040"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e1023 class=n-a></a>Kang YK, Ryu MH, Yoo C, <i> et al.</i>: Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncol.</i> 2013; <b>14</b>(12): 1175–82. <a target=xrefwindow id=d21312e1034 href="http://www.ncbi.nlm.nih.gov/pubmed/24140183">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1037 href="https://doi.org/10.1016/S1470-2045(13)70453-4">Publisher Full Text </a> | <a target=xrefwindow id=d21312e1041 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4347867">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718149040">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726282237"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e1054 class=n-a></a>Mir O, Cropet C, Toulmonde M, <i> et al.</i>: Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. <i>Lancet Oncol.</i> 2016; <b>17</b>(5): 632–41. <a target=xrefwindow id=d21312e1065 href="http://www.ncbi.nlm.nih.gov/pubmed/27068858">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1068 href="https://doi.org/10.1016/S1470-2045(16)00075-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726282237">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14266002"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e1081 class=n-a></a>Park SH, Ryu MH, Ryoo BY, <i> et al.</i>: Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. <i>Invest New Drugs.</i> 2012; <b>30</b>(6): 2377–83. <a target=xrefwindow id=d21312e1092 href="http://www.ncbi.nlm.nih.gov/pubmed/22270258">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1095 href="https://doi.org/10.1007/s10637-012-9795-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14266002">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d21312e1108 class=n-a></a>Montemurro M, Gelderblom H, Bitz U, <i> et al.</i>: Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. <i>Eur J Cancer.</i> 2013; <b>49</b>(5): 1027–31. <a target=xrefwindow id=d21312e1119 href="http://www.ncbi.nlm.nih.gov/pubmed/23140824">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1122 href="https://doi.org/10.1016/j.ejca.2012.10.009">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d21312e1131 class=n-a></a>Reichardt P, Blay JY, Gelderblom H, <i> et al.</i>: Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. <i>Ann Oncol.</i> 2012; <b>23</b>(7): 1680–7. <a target=xrefwindow id=d21312e1142 href="http://www.ncbi.nlm.nih.gov/pubmed/22357255">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1145 href="https://doi.org/10.1093/annonc/mdr598">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1157329"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e1155 class=n-a></a>Heinrich MC, Maki RG, Corless CL, <i> et al.</i>: Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. <i>J Clin Oncol.</i> 2008; <b>26</b>(33): 5352–9. <a target=xrefwindow id=d21312e1166 href="http://www.ncbi.nlm.nih.gov/pubmed/18955458">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1169 href="https://doi.org/10.1200/JCO.2007.15.7461">Publisher Full Text </a> | <a target=xrefwindow id=d21312e1173 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2651076">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1157329">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d21312e1186 class=n-a></a>Heinrich MC, Corless CL, Demetri GD, <i> et al.</i>: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. <i>J Clin Oncol.</i> 2003; <b>21</b>(23): 4342–9. <a target=xrefwindow id=d21312e1197 href="http://www.ncbi.nlm.nih.gov/pubmed/14645423">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1200 href="https://doi.org/10.1200/JCO.2003.04.190">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d21312e1209 class=n-a></a>Corless CL, Schroeder A, Griffith D, <i> et al.</i>: <i>PDGFRA</i> mutations in gastrointestinal stromal tumors: frequency, spectrum and <i>in vitro</i> sensitivity to imatinib. <i>J Clin Oncol.</i> 2005; <b>23</b>(23): 5357–64. <a target=xrefwindow id=d21312e1227 href="http://www.ncbi.nlm.nih.gov/pubmed/15928335">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1230 href="https://doi.org/10.1200/JCO.2005.14.068">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d21312e1239 class=n-a></a>von Mehren M, Tetzlaff ED, Macaraeg M, <i> et al.</i>: Dose escalating study of crenolanib besylate in advanced GIST patients with PDGFRA D842V activating mutations. <i>JCO.</i> 2016; <b>34</b>(15_suppl): 11010. <a target=xrefwindow id=d21312e1250 href="https://doi.org/10.1200/JCO.2016.34.15_suppl.11010">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d21312e1259 class=n-a></a>Blay JY, Heinrich MC, Hohenberger P, <i> et al.</i>: A randomized, double-blind, placebo-controlled, phase III study of crenolanib in advanced or metastatic GIST patients bearing a D842V mutation in <i>PDGFRA</i>: The CrenoGIST study. <i>JCO.</i> 2017; <b>35</b>(15_suppl): TPS11080–TPS11080. <a target=xrefwindow id=d21312e1273 href="https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS11080">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732068072"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e1282 class=n-a></a>Evans EK, Gardino AK, Kim JL, <i> et al.</i>: A precision therapy against cancers driven by <i>KIT/PDGFRA</i> mutations. <i>Sci Transl Med.</i> 2017; <b>9</b>(414): pii: eaao1690. <a target=xrefwindow id=d21312e1296 href="http://www.ncbi.nlm.nih.gov/pubmed/29093181">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1300 href="https://doi.org/10.1126/scitranslmed.aao1690">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732068072">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d21312e1314 class=n-a></a>Heinrich MC, Jones RL, von Mehren M, <i> et al.</i>: Clinical activity of BLU-285, a highly potent and selective KIT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST). Presented at: Annual Meeting of the Connective Tissue Oncology Society, 2017. Maui, HI. Oral presentation (#2803523). <a target=xrefwindow id=d21312e1319 href="http://www.blueprintmedicines.com/wp-content/uploads/2017/11/BLU-285-Presentation-by-Blueprint-Medicines-on-November-10-2017-at-the-CTOS-Annual-Meeting.pdf">Reference Source</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d21312e1328 class=n-a></a>Janku F, Razak ARA, Gordon MS, <i> et al.</i>: 1473OEncouraging activity of novel pan-KIT and PDGFRα inhibitor DCC-2618 in patients (pts) with Gastrointestinal Stromal Tumor (GIST). <i>Annals of Oncology.</i> 2017; <b>28</b>(suppl_5): mdx387. <a target=xrefwindow id=d21312e1339 href="https://doi.org/10.1093/annonc/mdx387">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/719895110"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e1348 class=n-a></a>van der Graaf WT, Blay JY, Chawla SP, <i> et al.</i>: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet.</i> 2012; <b>379</b>(9829): 1879–86. <a target=xrefwindow id=d21312e1359 href="http://www.ncbi.nlm.nih.gov/pubmed/22595799">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1362 href="https://doi.org/10.1016/S0140-6736(12)60651-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/719895110">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726858212"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e1375 class=n-a></a>Mir O, Brodowicz T, Italiano A, <i> et al.</i>: Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncol.</i> 2016; <b>17</b>(12): 1732–42. <a target=xrefwindow id=d21312e1386 href="http://www.ncbi.nlm.nih.gov/pubmed/27751846">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1389 href="https://doi.org/10.1016/S1470-2045(16)30507-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726858212">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725955155"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e1402 class=n-a></a>Chawla SP, Papai Z, Mukhametshina G, <i> et al.</i>: First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial. <i>JAMA Oncol.</i> 2015; <b>1</b>(9): 1272–80. <a target=xrefwindow id=d21312e1413 href="http://www.ncbi.nlm.nih.gov/pubmed/26378637">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1416 href="https://doi.org/10.1001/jamaoncol.2015.3101">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725955155">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d21312e1429 class=n-a></a>Sankhala KK, Jones RL, Chua VS, <i> et al.</i>: Lack of cardiac toxicity in patients treated with aldoxrubicin with doxorubicin equivalent doses beyond 1000mg/m2. <i>JCO.</i> 2018; <b>36</b>(15_suppl): 11585. <a target=xrefwindow id=d21312e1440 href="https://doi.org/10.1200/JCO.2018.36.15_suppl.11585">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726419924"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e1450 class=n-a></a>Tap WD, Jones RL, van Tine BA, <i> et al.</i>: Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. <i>Lancet.</i> 2016; <b>388</b>(10043): 488–97. <a target=xrefwindow id=d21312e1461 href="http://www.ncbi.nlm.nih.gov/pubmed/27291997">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1464 href="https://doi.org/10.1016/S0140-6736(16)30587-6">Publisher Full Text </a> | <a target=xrefwindow id=d21312e1468 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5647653">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726419924">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d21312e1481 class=n-a></a>Penel N, Bui BN, Bay JO, <i> et al.</i>: Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. <i>J Clin Oncol.</i> 2008; <b>26</b>(32): 5269–74. <a target=xrefwindow id=d21312e1492 href="http://www.ncbi.nlm.nih.gov/pubmed/18809609">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1495 href="https://doi.org/10.1200/JCO.2008.17.3146">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d21312e1504 class=n-a></a>Rosen G, Forscher C, Lowenbraun S, <i> et al.</i>: Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. <i>Cancer.</i> 1994; <b>73</b>(10): 2506–11. <a target=xrefwindow id=d21312e1515 href="http://www.ncbi.nlm.nih.gov/pubmed/8174046">PubMed Abstract </a> | <a target="xrefwindow" id="d21312e1518" href="https://doi.org/10.1002/1097-0142(19940515)73:10<2506::AID-CNCR2820731009&gt;3.0.CO;2-S">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726145832"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e1527 class=n-a></a>Schöffski P, Chawla S, Maki RG, <i> et al.</i>: Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial. <i>Lancet.</i> 2016; <b>387</b>(10028): 1629–37. <a target=xrefwindow id=d21312e1538 href="http://www.ncbi.nlm.nih.gov/pubmed/26874885">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1541 href="https://doi.org/10.1016/S0140-6736(15)01283-0">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726145832">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730126542"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e1554 class=n-a></a>Demetri GD, Schöffski P, Grignani G, <i> et al.</i>: Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. <i>J Clin Oncol.</i> 2017; <b>35</b>(30): 3433–9. <a target=xrefwindow id=d21312e1565 href="http://www.ncbi.nlm.nih.gov/pubmed/28854066">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1568 href="https://doi.org/10.1200/JCO.2016.71.6605">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730126542">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725788005"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e1581 class=n-a></a>Demetri GD, von Mehren M, Jones RL, <i> et al.</i>: Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. <i>J Clin Oncol.</i> 2016; <b>34</b>(8): 786–93. <a target=xrefwindow id=d21312e1592 href="http://www.ncbi.nlm.nih.gov/pubmed/26371143">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1595 href="https://doi.org/10.1200/JCO.2015.62.4734">Publisher Full Text </a> | <a target=xrefwindow id=d21312e1599 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5070559">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725788005">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725450166"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e1613 class=n-a></a>Garcia-Carbonero R, Supko JG, Manola J, <i> et al.</i>: Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. <i>J Clin Oncol.</i> 2004; <b>22</b>(8): 1480–90. <a target=xrefwindow id=d21312e1624 href="http://www.ncbi.nlm.nih.gov/pubmed/15084621">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1627 href="https://doi.org/10.1200/JCO.2004.02.098">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725450166">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726578834"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e1640 class=n-a></a>Gounder MM, Zer A, Tap WD, <i> et al.</i>: Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. <i>J Clin Oncol.</i> 2016; <b>34</b>(26): 3166–74. <a target=xrefwindow id=d21312e1651 href="http://www.ncbi.nlm.nih.gov/pubmed/27458288">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1654 href="https://doi.org/10.1200/JCO.2016.67.6346">Publisher Full Text </a> | <a target=xrefwindow id=d21312e1658 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5321073">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726578834">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d21312e1671 class=n-a></a>Gounder MM, Somaiah N, Attia S, <i> et al.</i>: Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study. <i>JCO.</i> 2018; <b>36</b>(15_suppl): 11512. <a target=xrefwindow id=d21312e1682 href="https://doi.org/10.1200/JCO.2018.36.15_suppl.11512">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733445116"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e1691 class=n-a></a>Chi Y, Fang Z, Hong X, <i> et al.</i>: Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma. <i>Clin Cancer Res.</i> 2018. <a target=xrefwindow id=d21312e1699 href="http://www.ncbi.nlm.nih.gov/pubmed/29895706">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1702 href="https://doi.org/10.1158/1078-0432.CCR-17-3766">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733445116">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d21312e1715 class=n-a></a>Chi Y, Yao Y, Wang S, <i> et al.</i>: Anlotinib for metastasis soft tissue sarcoma: A randomized, double-blind, placebo-controlled and multi-centered clinical trial. <i>JCO.</i> 2018; <b>36</b>(15_suppl): 11503. <a target=xrefwindow id=d21312e1726 href="https://doi.org/10.1200/JCO.2018.36.15_suppl.11503">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726973209"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e1735 class=n-a></a>Kollár A, Jones RL, Stacchiotti S, <i> et al.</i>: Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. <i>Acta Oncol.</i> 2017; <b>56</b>(1): 88–92. <a target=xrefwindow id=d21312e1746 href="http://www.ncbi.nlm.nih.gov/pubmed/27838944">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1749 href="https://doi.org/10.1080/0284186X.2016.1234068">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726973209">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d21312e1763 class=n-a></a>von Mehren M, Rankin C, Goldblum JR, <i> et al.</i>: Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. <i>Cancer.</i> 2012; <b>118</b>(3): 770–6. <a target=xrefwindow id=d21312e1774 href="http://www.ncbi.nlm.nih.gov/pubmed/21751200">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1777 href="https://doi.org/10.1002/cncr.26334">Publisher Full Text </a> | <a target=xrefwindow id=d21312e1781 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3576704">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d21312e1790 class=n-a></a>Agulnik M, Yarber JL, Okuno SH, <i> et al.</i>: An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. <i>Ann Oncol.</i> 2013; <b>24</b>(1): 257–63. <a target=xrefwindow id=d21312e1801 href="http://www.ncbi.nlm.nih.gov/pubmed/22910841">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1804 href="https://doi.org/10.1093/annonc/mds237">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d21312e1813 class=n-a></a>Dickson MA, D'Adamo DR, Keohan ML, <i> et al.</i>: Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. <i>Sarcoma.</i> 2015; <b>2015</b>: 532478. <a target=xrefwindow id=d21312e1824 href="http://www.ncbi.nlm.nih.gov/pubmed/26074722">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1827 href="https://doi.org/10.1155/2015/532478">Publisher Full Text </a> | <a target=xrefwindow id=d21312e1831 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4446476">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d21312e1840 class=n-a></a>Ray-Coquard IL, Domont J, Tresch-Bruneel E, <i> et al.</i>: Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. <i>J Clin Oncol.</i> 2015; <b>33</b>(25): 2797–802. <a target=xrefwindow id=d21312e1851 href="http://www.ncbi.nlm.nih.gov/pubmed/26215950">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1854 href="https://doi.org/10.1200/JCO.2015.60.8505">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d21312e1863 class=n-a></a>Fritchie K, Attia S, Okuno S, <i> et al.</i>: Abstract B237: CD105: A therapeutic target for sarcomas. <i>Mol Cancer Ther.</i> 2013; <b>12</b>(11 Suppl): B237. <a target=xrefwindow id=d21312e1874 href="https://doi.org/10.1158/1535-7163.TARG-13-B237">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d21312e1883 class=n-a></a>Hara H: Endoglin (CD105) and claudin-5 expression in cutaneous angiosarcoma. <i>Am J Dermatopathol.</i> 2012; <b>34</b>(7): 779–82. <a target=xrefwindow id=d21312e1891 href="http://www.ncbi.nlm.nih.gov/pubmed/23000880">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1894 href="https://doi.org/10.1097/DAD.0b013e318252fc32">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d21312e1904 class=n-a></a>Sankala KK, Riedel RF, Conry RM, <i> et al.</i>: Every Other Week Dosing of TRC105 (Endoglin Antibody) in Combination with Pazopanib in Patients with Advanced Soft Tissue Sarcoma. Presented at: Annual Meeting of the Connective Tissue Oncology Society, Maui, HI. Poster 265 (#2804349) 2017. </span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/5443957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e1916 class=n-a></a>Chugh R, Wathen JK, Patel SR, <i> et al.</i>: Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. <i>Clin Cancer Res.</i> 2010; <b>16</b>(19): 4884–91. <a target=xrefwindow id=d21312e1927 href="http://www.ncbi.nlm.nih.gov/pubmed/20724445">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1930 href="https://doi.org/10.1158/1078-0432.CCR-10-1177">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/5443957">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d21312e1943 class=n-a></a>Penel N, Le Cesne A, Bui BN, <i> et al.</i>: Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. <i>Ann Oncol.</i> 2011; <b>22</b>(2): 452–7. <a target=xrefwindow id=d21312e1954 href="http://www.ncbi.nlm.nih.gov/pubmed/20622000">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1957 href="https://doi.org/10.1093/annonc/mdq341">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727388875"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e1966 class=n-a></a>Kasper B, Gruenwald V, Reichardt P, <i> et al.</i>: Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). <i>Eur J Cancer.</i> 2017; <b>76</b>: 60–7. <a target=xrefwindow id=d21312e1977 href="http://www.ncbi.nlm.nih.gov/pubmed/28282612">PubMed Abstract </a> | <a target=xrefwindow id=d21312e1980 href="https://doi.org/10.1016/j.ejca.2017.02.001">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727388875">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/12590957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e1993 class=n-a></a>Gounder MM, Lefkowitz RA, Keohan ML, <i> et al.</i>: Activity of Sorafenib against desmoid tumor/deep fibromatosis. <i>Clin Cancer Res.</i> 2011; <b>17</b>(12): 4082–90. <a target=xrefwindow id=d21312e2004 href="http://www.ncbi.nlm.nih.gov/pubmed/21447727">PubMed Abstract </a> | <a target=xrefwindow id=d21312e2007 href="https://doi.org/10.1158/1078-0432.CCR-10-3322">Publisher Full Text </a> | <a target=xrefwindow id=d21312e2011 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3152981">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/12590957">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d21312e2024 class=n-a></a>Gounder MM, Mahoney MR, van Tine BA, <i> et al.</i>: Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105). <i>J Clin Oncol.</i> 2018; <b>36</b>(15_suppl): 11500. <a target=xrefwindow id=d21312e2035 href="https://doi.org/10.1200/JCO.2018.36.15_suppl.11500">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d21312e2045 class=n-a></a>West RB, Rubin BP, Miller MA, <i> et al.</i>: A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. <i>Proc Natl Acad Sci U S A.</i> 2006; <b>103</b>(3): 690–5. <a target=xrefwindow id=d21312e2056 href="http://www.ncbi.nlm.nih.gov/pubmed/16407111">PubMed Abstract </a> | <a target=xrefwindow id=d21312e2059 href="https://doi.org/10.1073/pnas.0507321103">Publisher Full Text </a> | <a target=xrefwindow id=d21312e2063 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1325107">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d21312e2072 class=n-a></a>Cupp JS, Miller MA, Montgomery KD, <i> et al.</i>: Translocation and expression of <i>CSF1</i> in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. <i>Am J Surg Pathol.</i> 2007; <b>31</b>(6): 970–6. <a target=xrefwindow id=d21312e2086 href="http://www.ncbi.nlm.nih.gov/pubmed/17527089">PubMed Abstract </a> | <a target=xrefwindow id=d21312e2090 href="https://doi.org/10.1097/PAS.0b013e31802b86f8">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d21312e2099 class=n-a></a>Cassier PA, Gelderblom H, Stacchiotti S, <i> et al.</i>: Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. <i>Cancer.</i> 2012; <b>118</b>(6): 1649–55. <a target=xrefwindow id=d21312e2110 href="http://www.ncbi.nlm.nih.gov/pubmed/21823110">PubMed Abstract </a> | <a target=xrefwindow id=d21312e2113 href="https://doi.org/10.1002/cncr.26409">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d21312e2122 class=n-a></a>Gelderblom H, Pérol D, Chevreau C, <i> et al.</i>: An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment. <i>J Clin Oncol.</i> 2013; <b>31</b> (15_suppl): abstr 10006. <a target=xrefwindow id=d21312e2133 href="http://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.10516">Reference Source</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d21312e2142 class=n-a></a>Holmgaard RB, Zamarin D, Lesokhin A, <i> et al.</i>: Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. <i>EBioMedicine.</i> 2016; <b>6</b>: 50–8. <a target=xrefwindow id=d21312e2153 href="http://www.ncbi.nlm.nih.gov/pubmed/27211548">PubMed Abstract </a> | <a target=xrefwindow id=d21312e2156 href="https://doi.org/10.1016/j.ebiom.2016.02.024">Publisher Full Text </a> | <a target=xrefwindow id=d21312e2160 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4856741">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d21312e2169 class=n-a></a>Tap WD, Wainberg ZA, Anthony SP, <i> et al.</i>: Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. <i>N Engl J Med.</i> 2015; <b>373</b>(5): 428–37. <a target=xrefwindow id=d21312e2180 href="http://www.ncbi.nlm.nih.gov/pubmed/26222558">PubMed Abstract </a> | <a target=xrefwindow id=d21312e2183 href="https://doi.org/10.1056/NEJMoa1411366">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d21312e2193 class=n-a></a>Tap WD, Gelderblom H, Stacchiotti S, <i> et al.</i>: Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT). <i>J Clin Oncol.</i> 2018; <b>36</b>(15_suppl): 11502. <a target=xrefwindow id=d21312e2204 href="https://doi.org/10.1200/JCO.2018.36.15_suppl.11502">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d21312e2213 class=n-a></a>Cassier PA, Italiano A, Gomez-Roca CA, <i> et al.</i>: CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. <i>Lancet Oncol.</i> 2015; <b>16</b>(8): 949–56. <a target=xrefwindow id=d21312e2224 href="http://www.ncbi.nlm.nih.gov/pubmed/26179200">PubMed Abstract </a> | <a target=xrefwindow id=d21312e2227 href="https://doi.org/10.1016/S1470-2045(15)00132-1">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d21312e2236 class=n-a></a>Tawbi HA, Burgess M, Bolejack V, <i> et al.</i>: Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. <i>Lancet Oncol.</i> 2017; <b>18</b>(11): 1493–501. <a target=xrefwindow id=d21312e2247 href="http://www.ncbi.nlm.nih.gov/pubmed/28988646">PubMed Abstract </a> | <a target=xrefwindow id=d21312e2250 href="https://doi.org/10.1016/S1470-2045(17)30624-1">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732571654"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e2259 class=n-a></a>D'Angelo SP, Mahoney MR, Van Tine BA, <i> et al.</i>: Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. <i>Lancet Oncol.</i> 2018; <b>19</b>(3): 416–26. <a target=xrefwindow id=d21312e2270 href="http://www.ncbi.nlm.nih.gov/pubmed/29370992">PubMed Abstract </a> | <a target=xrefwindow id=d21312e2273 href="https://doi.org/10.1016/S1470-2045(18)30006-8">Publisher Full Text </a> | <a target=xrefwindow id=d21312e2277 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6126546">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732571654">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d21312e2290 class=n-a></a>Wilky BA, Trucco MM, Kolonias D, <i> et al.</i>: A phase II trial of axitinib plus pembrolizumab for patients with advanced alveolar soft part sarcoma (ASPS) and other soft tissue sarcomas (STS). <i>J Clin Oncol.</i> 2018; <b>36</b>(15_suppl): 11547. <a target=xrefwindow id=d21312e2301 href="https://doi.org/10.1200/JCO.2018.36.15_suppl.11547">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733658064"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e2310 class=n-a></a>Lewin J, Davidson S, Anderson ND, <i> et al.</i>: Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma. <i>Cancer Immunol Res.</i> 2018; <b>6</b>(9): 1001–7. <a target=xrefwindow id=d21312e2321 href="http://www.ncbi.nlm.nih.gov/pubmed/30018044">PubMed Abstract </a> | <a target=xrefwindow id=d21312e2324 href="https://doi.org/10.1158/2326-6066.CIR-18-0037">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733658064">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d21312e2338 class=n-a></a>Vander Jagt TA, Davis LE, Thakur MD, <i> et al.</i>: Pseudoprogression of CNS metastatic disease of alveolar soft part sarcoma during anti-PDL1 treatment. <i>Radiol Case Rep.</i> 2018; <b>13</b>(4): 882–5. <a target=xrefwindow id=d21312e2349 href="http://www.ncbi.nlm.nih.gov/pubmed/29991973">PubMed Abstract </a> | <a target=xrefwindow id=d21312e2352 href="https://doi.org/10.1016/j.radcr.2018.05.013">Publisher Full Text </a> | <a target=xrefwindow id=d21312e2356 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6037874">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13975958"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e2365 class=n-a></a>Pollack SM, Jungbluth AA, Hoch BL, <i> et al.</i>: NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. <i>Cancer.</i> 2012; <b>118</b>(18): 4564–70. <a target=xrefwindow id=d21312e2376 href="http://www.ncbi.nlm.nih.gov/pubmed/22359263">PubMed Abstract </a> | <a target=xrefwindow id=d21312e2379 href="https://doi.org/10.1002/cncr.27446">Publisher Full Text </a> | <a target=xrefwindow id=d21312e2383 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3361576">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13975958">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d21312e2396 class=n-a></a>Lai JP, Rosenberg AZ, Miettinen MM, <i> et al.</i>: NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target. <i>Oncoimmunology.</i> 2012; <b>1</b>(8): 1409–10. <a target=xrefwindow id=d21312e2407 href="http://www.ncbi.nlm.nih.gov/pubmed/23243610">PubMed Abstract </a> | <a target=xrefwindow id=d21312e2410 href="https://doi.org/10.4161/onci.21059">Publisher Full Text </a> | <a target=xrefwindow id=d21312e2414 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3518519">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d21312e2423 class=n-a></a>Hemminger JA, Ewart Toland A, Scharschmidt TJ, <i> et al.</i>: The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas. <i>Mod Pathol.</i> 2013; <b>26</b>(2): 282–8. <a target=xrefwindow id=d21312e2434 href="http://www.ncbi.nlm.nih.gov/pubmed/22936067">PubMed Abstract </a> | <a target=xrefwindow id=d21312e2437 href="https://doi.org/10.1038/modpathol.2012.133">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732725726"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e2446 class=n-a></a>Drilon A, Laetsch TW, Kummar S, <i> et al.</i>: Efficacy of Larotrectinib in <i>TRK</i> Fusion-Positive Cancers in Adults and Children. <i>N Engl J Med.</i> 2018; <b>378</b>(8): 731–9. <a target=xrefwindow id=d21312e2460 href="http://www.ncbi.nlm.nih.gov/pubmed/29466156">PubMed Abstract </a> | <a target=xrefwindow id=d21312e2464 href="https://doi.org/10.1056/NEJMoa1714448">Publisher Full Text </a> | <a target=xrefwindow id=d21312e2467 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5857389">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732725726">F1000 Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727294853"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21312e2480 class=n-a></a>Drilon A, Siena S, Ou SI, <i> et al.</i>: Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discov.</i> 2017; <b>7</b>(4): 400–9. <a target=xrefwindow id=d21312e2491 href="http://www.ncbi.nlm.nih.gov/pubmed/28183697">PubMed Abstract </a> | <a target=xrefwindow id=d21312e2494 href="https://doi.org/10.1158/2159-8290.CD-16-1237">Publisher Full Text </a> | <a target=xrefwindow id=d21312e2498 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5380583">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727294853">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 02 Nov 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1737&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1737&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Duke University Medical Center, Durham, NC, USA<br/> <p> <div class=margin-bottom> Jennifer Choe <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Richard Riedel <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-1737/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 02 Nov 2018, 7:1737 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.15868.1">https://doi.org/10.12688/f1000research.15868.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2018 Choe J and Riedel R. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=17324 data-id=15868 data-downloads="" data-views="" data-scholar="10.12688/f1000research.15868.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-1737/v1/pdf?article_uuid=35a64fa8-520d-49be-8cc3-e10084333a24" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.15868.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Choe J and Riedel R. Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas [version 1; peer review: 2 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1737 (<a href="https://doi.org/10.12688/f1000research.15868.1" target=_blank>https://doi.org/10.12688/f1000research.15868.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=15868 id=mobile-track-article-signin-15868 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/15868?target=/articles/7-1737"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=17324 /> <input name=articleId type=hidden value=15868 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Shreyaskumar Patel</strong>, Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Bernd Kasper</strong>, Sarcoma Unit, Interdisciplinary Tumor Center Mannheim, Mannheim University Medical Center, University of Heidelberg, Germany </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 02 Nov 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1737&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1737&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=18252-39842></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=40772-39841></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-1737/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>02 Nov 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Shreyaskumar Patel</strong>, Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Bernd Kasper</strong>, Sarcoma Unit, Interdisciplinary Tumor Center Mannheim, Mannheim University Medical Center, University of Heidelberg, Germany </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-1737&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-1737/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Making progress in a rare disease: emerging...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-1737/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-1737/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-1737/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Choe J and Riedel R');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-1737/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-1737",
            templates : {
                twitter : "Making progress in a rare disease: emerging therapeutics in soft.... Choe J and Riedel R, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-1737/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/15868/17324")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "17324");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "39841": 0,
                           "39842": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "eb3af794-a54e-4baf-83b4-74b4da82bb8d";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1737.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1737.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1737.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-1737.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-1737.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>